Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Bex

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
World Journal of Urology|November 16, 2019
Prediction of early (30-day) and late (30-90-day) mortality after radical cystectomy in a comprehensive cancer centre over two decadesM L Korbee, C S Voskuilen, K Hendricksen, et al.
British Journal of Cancer|June 5, 2003
Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinomaN Verra, R Jansen, G Groenewegen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2025
Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinomaB I Rini, L Albiges, X Tang, et al.
BJUI Compass|June 19, 2023
Variation in the management of cT1 renal cancer by surgical hospital volume: A nationwide studyH Yildirim, M S Schuurman, C V Widdershoven, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|December 3, 2014
[Ischemia is not an independent predictive factor of chronic renal failure after partial nephrectomy in a solitary kidney in patients without pre-operative renal insufficiency]R Bahi, G Pignot, Y Hammoudi, et al.
Urologic Oncology|February 23, 2013
Predictive factors of chronic kidney disease stage V after partial nephrectomy in a solitary kidney: a multi-institutional studyG Verhoest, J J Patard, E Oger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2015
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†A Kramar, S Negrier, R Sylvester, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
World Journal of Urology|November 16, 2019
Prediction of early (30-day) and late (30-90-day) mortality after radical cystectomy in a comprehensive cancer centre over two decadesM L Korbee, C S Voskuilen, K Hendricksen, et al.
British Journal of Cancer|June 5, 2003
Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinomaN Verra, R Jansen, G Groenewegen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2025
Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinomaB I Rini, L Albiges, X Tang, et al.
BJUI Compass|June 19, 2023
Variation in the management of cT1 renal cancer by surgical hospital volume: A nationwide studyH Yildirim, M S Schuurman, C V Widdershoven, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|December 3, 2014
[Ischemia is not an independent predictive factor of chronic renal failure after partial nephrectomy in a solitary kidney in patients without pre-operative renal insufficiency]R Bahi, G Pignot, Y Hammoudi, et al.
Urologic Oncology|February 23, 2013
Predictive factors of chronic kidney disease stage V after partial nephrectomy in a solitary kidney: a multi-institutional studyG Verhoest, J J Patard, E Oger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2015
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†A Kramar, S Negrier, R Sylvester, et al.
Pageof 6